Welcome to our dedicated page for UNITED STATES ANTIMONY SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITED STATES ANTIMONY's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITED STATES ANTIMONY's regulatory disclosures and financial reporting.
United States Antimony Corp executive compensation update: VP and General Manager, BRZ, Jeffrey Russell Fink reported new equity awards tied to his role at the company. On January 15, 2026, he received restricted stock units covering 22,955 shares of common stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 7,652 shares, will vest on January 15, 2027, and additional one-third portions will vest on January 18, 2028 and January 19, 2029, as long as he continues to serve the company.
He was also granted a stock option covering 40,054 shares of common stock at an exercise price of $8.29 per share. This option vests only if specified performance measures in the grant are achieved at any time during its 10-year term, again requiring continued service through any vesting date.
United States Antimony Corporation reported an equity compensation grant to its SVP and Chief Financial Officer, Richard R. Isaak. On January 15, 2026, he received restricted stock units covering 73,086 shares of common stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 24,362 shares, will vest on January 15, 2026, with additional one-third installments vesting on January 15, 2027 and January 18, 2028, contingent on continued service. He was also granted a stock option over 82,169 shares of common stock with an exercise price of $8.29 per share. The option vests upon meeting specified performance measures at any time during its 10-year term, also subject to continued service.
United States Antimony Corp. granted equity awards to director John M. Keane as part of its Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he received time-based restricted stock units representing 7,464 shares of common stock, vesting in three equal installments of 2,488 shares on January 15, 2027, January 18, 2028, and January 16, 2029, subject to continued service. He was also granted a time-based stock option for 4,597 shares at an exercise price of $8.29 per share, vesting in three installments of 1,533 shares on the same dates, also conditioned on continued service as a director.
United States Antimony Corp director Michael A. McManus Jr. reported equity awards under the company’s Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he acquired 6,635 shares of common stock at $0 as part of a time-based restricted stock unit grant. These shares represent one-third of a larger 19,903-share RSU award, with the remaining portions scheduled to vest in equal tranches on January 15, 2027 and January 18, 2028, subject to his continued service.
He was also granted a stock option for 12,259 shares of common stock at an exercise price of $8.29 per share, vesting in three equal installments of 4,087 shares on January 15, 2027, January 18, 2028, and January 16, 2029, again contingent on continued service. Following these transactions, McManus beneficially owned 538,600 shares of common stock directly.
United States Antimony Corp. director Joseph A. Carrabba reported new equity awards and share ownership changes. On January 15, 2026, he acquired 6,635 shares of common stock at a price of $0, representing the first one-third tranche of a 19,903-share time-based restricted stock unit award under the Amended & Restated 2023 Equity Incentive Plan. After this transaction, he beneficially owned 112,702 shares of common stock directly.
On the same date, he was also granted a stock option covering 12,259 shares of common stock at an exercise price of $8.29 per share. The option is scheduled to vest in three equal installments of 4,087 shares each on January 15, 2027, January 18, 2028 and January 16, 2029, subject to his continued service through each vesting date.
United States Antimony Corp. director Blaise A. Aguirre reported new equity awards under the company’s Amended & Restated 2023 Equity Incentive Plan. On January 15, 2026, he acquired 6,635 shares of common stock at $0 as the first vesting tranche of a 19,903-share time-based restricted stock unit award. After this vesting, he beneficially owned 496,001 common shares directly.
On the same date, he was also granted a stock option for 12,259 shares with an exercise price of $8.29 per share. This option vests in three equal installments of 4,087 shares each on January 15, 2027, January 18, 2028, and January 16, 2029, subject to his continued service. These awards align his compensation more closely with the future performance of United States Antimony Corp.
United States Antimony Corporation reported that it has closed on the acquisition of a critical minerals flotation facility located in Radersburg, Montana. The facility, which is fully operational and situated between Helena and Bozeman, was acquired on January 16, 2026 for $4.75 million in cash, representing an immediate investment outflow.
The company has also budgeted approximately $2 million in future capital expenditures to make specific improvements to the newly acquired property and equipment. Details of the transaction and planned upgrades are described further in a related press release furnished as an exhibit.
United States Antimony Corp director Jon R. Marinelli reported new equity-based awards tied to his service with the company. He was granted derivative rights over 24,509 shares of common stock through a time-based restricted stock unit award under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 8,170 shares, will vest on December 4, 2026, with additional one‑third portions vesting on December 4, 2027 and December 4, 2028, if he continues in service.
Marinelli was also granted stock options covering 15,182 shares of common stock at an exercise price of $6.12 per share. These options vest in three equal installments of 5,061 shares on December 4, 2026, December 4, 2027, and December 4, 2028, contingent on his continued service through each vesting date.
United States Antimony Corporation filed a current report to let investors know it has issued a new shareholder letter. The company states that the letter, dated January 5, 2026, has been provided as Exhibit 99.1 to this report and is incorporated by reference. The information is furnished under Regulation FD, which means it is intended to share the same information with all investors at the same time rather than being treated as formally filed financial statements.
United States Antimony Corporation (UAMY) reported that its Board of Directors has appointed Jon R. Marinelli as a new director, effective November 24, 2025. With his addition, the Board increases to seven members, of which five are independent, and he will also serve as Chairman of a newly formed Finance Committee.
Marinelli brings more than 25 years of experience in capital markets, M&A, and strategic advisory work, including leadership roles at BMO Capital Markets and Deutsche Bank’s natural resources group, and has advised on over $285 billion in transactions. He will serve until the next annual shareholder meeting under the company’s standard non-employee director compensation program, and there are no related-party transactions requiring disclosure.